Diabetes: A relationship between plasma kinetic peptide release enzyme levels and cardiovascular risk in patients with type 1 diabetes.

In a recent study published in Diabetes, an authoritative journal in the field of diabetes, researchers aimed to clarify the relationship between diabetes control and complications testing (DCCT)/diabetes intervention and complication epidemiology (EDIC) in the study of type 1 diabetes (T1D) cohort plasma peptide release enzyme levels and cardiovascular disease (CVD) outcomes and major adverse cardiovascular events (MACEs).
test baseline (1983-1989), DCCT test mid-point (1988-1991), DCCT test end (1993) and EDIC test 4-6 years (1997-1997 In 1999), 8-10 (2001-2003) and 11-13 (2004-2006), the researchers measured longitudinal levels of kinetic peptide release enzymes in the plasma of 693 subjects.
used the Cox proportional risk regression model to assess the association between plasma kinetic peptide release enzyme levels and CVD risk.
In unaljusted models, higher plasma kinetic peptide release enzyme levels were associated with a higher risk of CVD during DCCT/EDIC tests (plasma kinetic peptide release enzyme levels increased by 20 nM per HR-1.16; p-0.0177).
the correlation between plasma kinetic peptide release enzyme levels and any CVD risk remained significant during EDIC follow-up, after correcting the correct age and average HbA1c (HR=1.20; p=0.0082) and the fully adjusted model of other cardiovascular risk factors (HR=1.17; p=0.0330).
for MACE, the edIC test period was not corrected (HR=1.25; p=0.0145), the lowest correction (HR=1.23; p=0.0417) and the full correction (HR=1.27; p=0.0328) models had a higher level of plasma peptide release enzymes associated with a higher risk.
these new findings suggest that plasma peptide release enzyme levels are associated with the risk of CVD and MACE in patients with T1D.
.